Prof. PeptideProf. Peptide

PDA (Pentadeca Arginate)

Recovery & Tissue RepairResearch-Grade

Last reviewed: July 13, 2026

Quick Facts

What it is
Pentadeca Arginate — a synthetic 15-amino-acid, arginate-stabilized peptide that is the salt-form variant of BPC-157 (same sequence), studied for tissue repair and recovery.
How it's taken
Subcutaneous injection, once or twice daily
Half-life
Not characterized in humans
Typical research dose
No published dose exists for PDA or BPC-157; 250–500 mcg subcutaneously once or twice daily is a community-reported figure, not derived from any cited study
Research status
Not FDA-approved — research use only. Shares BPC-157's FDA position: nominated but withdrawn (previously Category 2), not in Category 1.
On this page
  1. 1.Where to source PDA
  2. 2.What is PDA (Pentadeca Arginate)?
  3. 3.PDA vs BPC-157: what's actually different?
  4. 4.How does PDA work?
  5. 5.What is PDA researched for?
  6. 6.How is PDA dosed?
  7. 7.What are the side effects of PDA?
  8. 8.What are the limitations of PDA research?
  9. 9.PDA FAQ
  10. 10.References
  11. 11.Published Studies

Where to source PDA

PDA is not FDA-approved and, as a BPC-157 variant, has no FDA compounding authorization (BPC-157: nominated but withdrawn from Category 2, not in Category 1, per FDA’s page current as of April 22, 2026). Research-grade material is sold by specialty peptide vendors for laboratory use only. The vendors highlighted below have been vetted for transparent third-party testing, traceable batch documentation, and verified discount codes.

Ion Peptide15% off
Professor's Pick
Shop Ion Peptide
EZ Peptides10% off

Janoshik-tested · COA per batch

Shop EZ Peptides
Ameano Peptides10% off

Certificates checked at Janoshik

Shop Ameano Peptides
Compare prices across 3 vendors

See all 88 verified vendors

What is PDA (Pentadeca Arginate)?

Pentadeca Arginate (PDA) is the arginate-salt form of BPC-157 — the same 15-amino-acid synthetic peptide (sequence GEPPPGKPADDAGLV), supplied with an arginine counterion instead of the acetate counterion used in conventional BPC-157. In plain terms, PDA is essentially a salt-form variant of BPC-157: the peptide that reaches tissue is the same molecule, so PDA has no independent research base of its own. It is marketed as a more stable, upgraded version, but as of 2026 no peer-reviewed study has investigated PDA as a distinct compound.

Evidence honesty: The widely-repeated claim that PDA is “1,000× more stable than BPC-157 acetate” is unpublished vendor marketing, not a peer-reviewed finding — there is no head-to-head study behind it. Every mechanistic and tissue-repair claim for PDA is extrapolated from the BPC-157 literature, which is itself almost entirely preclinical. PDA is best evaluated as a salt-form variant of BPC-157, on the (preclinical) BPC-157 evidence base.

What is genuinely known:

  • PDA is the arginate salt of the same peptide as BPC-157 — identical amino-acid sequence
  • Its proposed mechanisms (angiogenesis, growth-factor and collagen support, tendon-to-bone signaling) are BPC-157's, demonstrated in animal models
  • No peer-reviewed study has investigated PDA specifically; a 2025 systematic review of BPC-157 found only one small human study; two other small, uncontrolled human papers fall outside its scope
  • The “1,000× stability” and “upgraded BPC-157” claims are unverified vendor marketing
  • It shares BPC-157's FDA position (nominated but withdrawn, previously Category 2; not in Category 1) and is sold research-use-only

Common research dose: Extrapolated from BPC-157 protocols — typically 250–500 mcg subcutaneously once or twice daily in 4–8 week cycles. No PDA-specific pharmacokinetic data exists.

Where to buy: PP maintains a vetted list of peptide vendors with verified discount codes. See Verified Discount Codes for current options.

PDA vs BPC-157: what's actually different?

The honest answer: only the salt. PDA is the arginate salt of the same 15-amino-acid peptide as BPC-157 (sequence GEPPPGKPADDAGLV) — an arginine counterion in place of the acetate counterion. The active peptide is chemically identical; a salt swap changes how the powder is packaged, not the peptide that reaches tissue.

  1. Same peptide, different counterion. BPC-157 is typically supplied as an acetate salt; PDA (Pentadeca Arginate) is supplied as an arginate salt. Once reconstituted and dosed, the same pentadecapeptide is delivered.
  2. The "1,000× more stable" claim is unpublished vendor marketing. No peer-reviewed study has measured the arginate salt's stability against the acetate salt, and no head-to-head comparison has been published. The specific figure has no citable primary source — treat it as an unverified marketing claim, not a fact.
  3. No PDA-specific research exists. As of 2026, no peer-reviewed study has investigated Pentadeca Arginate as a distinct molecule. Everything below is inherited from the BPC-157 literature, which is itself almost entirely preclinical.
  4. Why the salt form appeared. Arginate salts are used across pharmaceutical chemistry to adjust solubility and handling. Whether that yields any meaningful real-world advantage for this peptide is untested — plausible in principle, unproven in practice.

How does PDA work?

Because PDA delivers the same peptide as BPC-157, its proposed mechanisms are BPC-157's mechanisms — none are specific to the arginate salt. In animal models the parent peptide acts through angiogenesis, growth-factor modulation, the FAK-paxillin pathway, nitric-oxide modulation, and gut-brain-axis effects. These are the most-studied pathways for the peptide; they have not been separately re-demonstrated for the arginate form.

  1. Angiogenesis promotion [1]. The peptide upregulates VEGF and endothelial nitric oxide synthase (eNOS), stimulating new blood-vessel formation and improving delivery of oxygen and nutrients to injured tissue in animal models.
  2. Growth-factor modulation [2]. Increased EGR-1 expression drives fibroblast proliferation and collagen synthesis — the cells and matrix that rebuild connective tissue after injury.
  3. FAK-paxillin pathway [3]. In tendon and ligament tissue the peptide activates FAK-paxillin signaling, associated with improved tendon-to-bone insertion strength and collagen organization in rodent studies.
  4. Nitric-oxide modulation. The peptide modulates nitric-oxide synthesis bidirectionally, an effect linked to its anti-inflammatory and vascular actions in animal models.
  5. Gut-brain axis [4]. In animals the peptide interacts with dopaminergic and serotonergic systems, the basis for its reported neuroprotective and gut-healing effects. All of this is BPC-157 data applied to PDA by chemical identity, not by direct study of PDA.

What is PDA researched for?

There is no PDA-specific research program. The applications below are the BPC-157 evidence base — overwhelmingly rodent studies — that PDA inherits by being the same peptide. No completed Phase 2 or 3 human trial exists for either form, and a 2025 systematic review of BPC-157 found only one small human study.

  1. Tendon and ligament repair [3][5]. Multiple rat studies report faster Achilles-tendon and rotator-cuff healing; a 2025 systematic review analyzed 36 BPC-157 studies and found consistent benefit across musculoskeletal animal models.
  2. Muscle injury recovery [6]. Crush- and transection-injury models show accelerated functional recovery and reduced fibrotic scarring.
  3. Gastrointestinal protection [4]. The most established research area for the parent peptide — protection against NSAID-induced gastric lesions and support of ulcer and anastomosis healing in animal models.
  4. Human evidence is minimal. The single small human study cited in the 2025 review — an uncontrolled retrospective chart review in which 11 of 12 knee-pain patients given BPC-157 alone, and 14 of 16 overall, reported improvement (Lee & Padgett 2021) — is one of three small, uncontrolled human papers for BPC-157, all by the same lead author; the other two are an interstitial cystitis series (n=12) and an IV safety study (n=2). None tested PDA.

How is PDA dosed?

PDA itself has zero published dosing data — a PubMed search for "pentadeca arginate" returns no records as of 2026. What follows is split into what the BPC-157 literature actually administered (which PDA inherits only by chemical identity, not by direct study) and the community-reported human doses that circulate for both BPC-157 and PDA, which are not derived from any single published protocol.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

Need to calculate a dose?

Use the Prof. Peptide dosage calculator for accurate reconstitution and dosing math.

Open Calculator

What the cited literature administered

  1. No PDA studies exist. As of 2026, PubMed has zero records for “pentadeca arginate.” Every figure below is BPC-157 data, not PDA data.
  2. Vasireddi et al. 2025 (HSS J; PMID 40756949) — systematic review, Animal Model evidence level for 35 of 36 included studies. Preclinical BPC-157 studies dosed rodents on a mg/kg body-weight basis, not the fixed human mcg amounts circulated in research-peptide communities; the review does not convert those doses to a human equivalent.
  3. The human data is Human Observational, not a dosing protocol. The review's single clinical study was a retrospective chart review with no control group: in the primary paper (Lee & Padgett 2021), 11 of 12 patients given an intra-articular BPC-157 injection alone, and 14 of 16 overall, reported improvement in knee pain. The abstract does not report the injected dose, and the route (intraarticular, one-time) is not the repeated subcutaneous regimen described in community use below. Two other small, uncontrolled papers by the same lead author exist outside the review: bladder injections for interstitial cystitis (n=12) and an IV safety study (n=2).
  4. Pharmacokinetics (BPC-157, animal data). The review reports a half-life under 30 minutes, hepatic metabolism, and renal clearance — again, animal pharmacokinetic data, not a verified human profile.
  5. Adverse events in the cited literature. Preclinical (animal) safety studies showed no adverse effects across the organ systems examined. The review explicitly states no clinical safety data were found for BPC-157 in humans — a gap PDA inherits in full, on top of having no safety data of its own.

Community-reported practice (unverified)

  1. Standard injectable. 250 mcg subcutaneously once daily, or 250 mcg twice daily for stronger effect. This figure is not stated in any published BPC-157 or PDA study — it is a community convention, commonly described as a human-equivalent extrapolation from the animal dosing above, but no single cited source performs that conversion.
  2. Higher injectable. 500 mcg once or twice daily for severe injuries or post-surgical use, per community reports only.
  3. Route diverges from the human data point. Community practice is repeated subcutaneous injection, often near the injury site; the three small human papers used single knee or bladder injections and a two-day IV infusion. None is the same regimen.
  4. Cycle length. 4–8 weeks for routine recovery; up to 12 weeks for chronic or post-surgical use — community convention, not tested in any cited study.

Reconstitution. PDA research vials are typically 5 mg or 10 mg. Because community-reported doses are small (250–500 mcg), a 2 mL reconstitution is the common convention — it gives clean whole-number units across the typical range. All units below are measured on a U-100 insulin syringe (100 units = 1 mL); the table assumes a 5 mg vial. This is reconstitution arithmetic only, not a validated dose.

BAC waterConcentration250 mcg dose500 mcg dose
1 mL5 mg/mL5 units10 units
2 mL2.5 mg/mL10 units20 units

Converting mg to syringe units and planning reconstitution is covered in the dosage calculator . Insulin-syringe mechanics and subcutaneous technique are covered in the syringes and injection technique guide.

What are the side effects of PDA?

No PDA-specific safety study exists. The expected profile is BPC-157's: in animal studies the parent peptide has no toxic dose identified across decades of rodent work, but there are no completed long-term human safety trials for either form. Because the arginine counterion is the only difference, no distinct safety signal is anticipated — but this is inference, not tested fact.

  1. Injection-site reactions. Mild redness or irritation, typically transient — the most commonly reported effect in user protocols.
  2. Occasional mild dizziness or headache. Reported inconsistently on initial doses; usually self-limiting.
  3. No characterized long-term human safety data. No completed Phase 2 or 3 trials exist for BPC-157 or PDA; human safety beyond anecdotal use is not formally validated.
  4. Theoretical tumor-stimulation concern. The peptide's angiogenic activity raises a theoretical concern for anyone with active malignancy, though no such signal has appeared in the available animal or limited human data.

What are the limitations of PDA research?

This is the most important section on the page. PDA is marketed as an upgraded BPC-157, but the evidence supporting that framing is thin to nonexistent.

No peer-reviewed study has investigated Pentadeca Arginate as a distinct molecule as of 2026. Its entire research rationale is borrowed from BPC-157, whose own evidence is almost exclusively preclinical (rodent) — a 2025 systematic review found only one small human study, and two other small, uncontrolled papers fall outside its scope.

The headline marketing claim — that the arginate salt is roughly 1,000× more stable than BPC-157 acetate — is unpublished vendor material with no citable primary source. It has not been demonstrated in any peer-reviewed, head-to-head study.

Regulatory status is inherited, not improved. FDA lists BPC-157 among bulk drug substances “nominated but withdrawn” — previously in Category 2, now in neither Category 2 nor Category 1 (FDA page current as of April 22, 2026); as a salt-form variant of the same peptide, PDA has no separate status. Research-grade material is sold for laboratory use only (RUO) and is not approved for human use.

Bottom line: PDA is best understood as a salt-form variant of BPC-157, not a separately validated compound. The evidence that applies to it is the (preclinical) BPC-157 evidence base; no controlled data supports any PDA-specific superiority claim.

PDA FAQ

Is PDA the same thing as BPC-157?

Essentially, yes. Pentadeca Arginate (PDA) is the arginate-salt form of BPC-157 — the identical 15-amino-acid peptide (sequence GEPPPGKPADDAGLV), paired with an arginine counterion instead of the acetate counterion used in conventional BPC-157. The active peptide is the same molecule; only the salt differs. That means PDA has no separate published evidence base of its own — its research rationale is inherited entirely from BPC-157.

Is PDA really 1,000× more stable than BPC-157?

That claim is unpublished vendor marketing, not a peer-reviewed finding. As of 2026 no controlled, peer-reviewed study has measured the comparative stability of the arginate salt versus the acetate salt, and no head-to-head data has been published. Arginate salts can in principle affect solubility and shelf stability, but the specific '1,000×' figure is a marketing number with no citable source, and should be treated as an unverified claim.

Is there any research specifically on PDA?

As of 2026, no peer-reviewed study has investigated Pentadeca Arginate as a distinct molecule. Every mechanistic and tissue-repair claim made for PDA is extrapolated from the BPC-157 literature, which is itself almost entirely preclinical (rodent) work. A 2025 systematic review of BPC-157 in orthopaedic sports medicine identified only one small human study; two other small, uncontrolled papers by the same lead author (interstitial cystitis, n=12; IV safety, n=2) fall outside its scope. The human evidence is thin even for the parent compound.

How is PDA dosed?

There is no PDA-specific pharmacokinetic data, and no published BPC-157 study specifies a human subcutaneous dosing protocol either — the animal literature doses rodents by body weight (mg/kg), and the three small, uncontrolled human papers (by the same lead author) used single injections into the knee (n=17) or bladder (n=12) and a two-day IV infusion (n=2), not a repeated subcutaneous regimen. Community sources report 250–500 mcg subcutaneously once or twice daily in 4–8 week cycles; this figure comes from community practice, not from any cited study of BPC-157 or the arginate salt.

What is the FDA status of PDA?

PDA is not FDA-approved. FDA lists BPC-157 among bulk drug substances “nominated but withdrawn” — previously in Category 2, now in neither Category 2 nor Category 1 (FDA page current as of April 22, 2026); neither status authorizes compounding. Because PDA is a salt-form variant of the same peptide, it falls under the same regulatory umbrella. It is sold only as a research-use-only (RUO) laboratory chemical, not as an approved drug.

Where can I buy PDA?

PDA is sold by specialty research-peptide vendors as a research-use-only material. PP maintains a list of vetted vendors with verified discount codes — see Verified Discount Codes .

References

  1. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors. Curr Pharm Des. 2018;24(18):1972-1989. https://pubmed.ncbi.nlm.nih.gov/29998800/
  2. Tkalcevic VI, Cuzic S, Brajsa K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol. 2007;570(1-3):212-21. https://pubmed.ncbi.nlm.nih.gov/17628536/
  3. Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-80. https://pubmed.ncbi.nlm.nih.gov/21030672/
  4. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. https://pmc.ncbi.nlm.nih.gov/articles/PMC5333585/
  5. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/
  6. Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res. 2006;24(5):1109-17. https://pubmed.ncbi.nlm.nih.gov/16609979/
  7. McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Health. Curr Rev Musculoskelet Med. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/

Published Studies

There are no published studies on Pentadeca Arginate itself. The summaries below are the BPC-157 papers that define the evidence base PDA inherits — read them as parent-compound research, not as PDA data.

Frontiers in Pharmacology · 2021Open Access
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing →

Sikiric P, Seiwerth S, Rucman R, et al.

A comprehensive review of BPC-157’s wound-healing properties across more than 25 years of animal research — documenting accelerated healing of skin wounds, burns, ulcers, and fistulas through angiogenesis, collagen deposition, and nitric-oxide-system modulation. This is the parent-compound evidence base that PDA (as the arginate salt of the same peptide) draws on; note that the review concerns BPC-157 itself, not the arginate variant.

HSS Journal / PMC · 2025Open Access
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review →

Vasireddi N, Hahamyan H, Salata MJ, et al.

The most current systematic review of BPC-157 for musculoskeletal injuries — 36 studies from 1993 to 2024, overwhelmingly animal models. It identified only one small human study, a retrospective chart review of intra-articular injections for knee pain (in the primary paper, 11 of 12 patients given BPC-157 alone, and 14 of 16 overall, reported improvement; no control group) and concluded that, while preclinical results are promising, risks remain from unregulated manufacturing and the absence of formal human safety data. This is the key honesty anchor for PDA: even the parent compound has essentially no human trial base.

Curr Rev Musculoskelet Med / PMC · 2025Open Access
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Health →

McGuire FP, Martinez R, Lenz A, et al.

A 2025 narrative review weighing BPC-157’s regenerative promise against its risks — emphasizing that the evidence is preclinical, that manufacturing is unregulated, and that BPC-157’s regulatory position (then FDA Category 2) reflected unresolved safety questions. Applies directly to PDA, which inherits both the mechanistic rationale and the regulatory status of BPC-157.

Tissue RepairBPC-157 VariantSalt FormResearch-Grade

Related Peptides

TB-500GHK-CuKPVWolverine Stack

Compare

See the full BPC-157 profile

We may earn commissions from peptide vendor affiliate links.

Have a question about PDA (Pentadeca Arginate)? Send us an email